Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC

Launched by UNIVERSITÀ DEGLI STUDI DI FERRARA · Feb 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called salbutamol, which is usually used to help open up the airways, in patients who are struggling to breathe due to acute respiratory failure from pneumonia. The researchers want to see if using a special device called a vibrating mesh nebulizer to deliver salbutamol can make it easier for these patients to breathe and improve how well their lungs are working. They will measure various breathing patterns and lung functions to see if this method is safe and effective.

To participate in this study, patients need to be between 18 and 90 years old, be critically ill with respiratory failure caused by pneumonia, and be receiving oxygen therapy. However, certain individuals, such as those with severe breathing problems or specific heart conditions, may not be eligible. If someone qualifies and agrees to take part, they can expect to be monitored closely while receiving the treatment, and their breathing will be assessed through various tests. This trial is not yet recruiting participants, but it aims to gather important information that could help improve care for patients with serious breathing issues in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Age \> 18, \< 90 years
• • Non-intubated critically ill patients with AHRF due to pneumonia (diagnosis is based on the presence of infiltrates on chest X-ray and the onset of clinical signs of infection less than 7 days earlier)
• • PaO2/FiO2 ≤ 300 mmHg
• • Patients receiving oxygen therapy
• Exclusion Criteria:
• • • Age \< 18 years
• • Hypercapnia (PaCO2 \> 50 mmHg)
• • Hemodynamic instability (Systolic blood pressure \< 90 mmHg or Mean arterial pressure \< 60 or high dose of vasoactive drugs)
• • Tachycardia or tachyarrhythmia (HR \> 130 b/min)
• • Known allergy or intolerance to salbutamol
• • Patient has received inhaled therapy with short-acting beta 2 agonists \< 8 hours before or with long-acting beta 2 agonists \< 24 hours before
• • Acute exacerbation of COPD or bronchial asthma
• • Cardiogenic pulmonary edema
• • GCS ≤ 12
• • Contraindication for EIT (e.g. ICD)
• • Pregnancy
• • Patient refuses to participate